PPARA and metabolic syndrome: Of the 77 tested compounds, the isoflavones 55a, 55c, 55e and 55i were identified as novel potent dual PPARα and γ agonists, which could serve as future leads in PPAR-related disorders that include type II diabetes mellitus and metabolic syndrome [5].